The Numbers I used was taken from another post I posted
The Numbers I used was taken from another post I posted stating that I assumed full dilution and no debit. I apologize for the confusion and should of probably restated that with that post as well. It is going to take dilution and/or debts to bring the products through the clinical trials and to market. I think most shareholders realize that and are expecting dilution to occur. Hence, that's one of the reasons why I posted those numbers. However a 1 for 500 reverse split is absurd and that is the other reason. Predicting how much OWCP will be worth, what there A/S, and O/S in the future obviously is the key on deciding what reverse split should be allowed and how much interest long term investors on the OTC and NASDAQ will have. Remember this went to 3.23 on the promise of market ready product and REVENUE. When investors realized this was years down the road and the truth was market 3 years ready product it was time to get out. Hence the low share price. When there is market ready product and the promise of REVENUE the price will go up. Therefore I posted those numbers to calculate long term value based on when (if?) OWCP became worth 1 Billion and 10 Billion dollars with full dilution and no debt.
If you like do some calculations on how much clinical trials costs at Sheba and just how much debt or dilution OWCP would need to achieve their goals without REVENUE to get their first product on the market.
I prefer basing my short term and long term investments based on calculations. I prefer to base my day trade and short term investments on shareholders beliefs and attitudes. While I like to make my investments fun and don't mind criticism, it scares me when I see some on the other board who have been bashing this for 2 years. It scares me even more when I have seen those who supported OWCP now trash talk it. I personally like to get in when this is oversold and get out when it's not.
Which makes me realize R/S or not, there is going to be a wild roller coaster ride coming up! Since I missed my last shot to get out at 0.067 3 weeks ago like I was suppose to, I know have to buy more at the bottom. This is the game I play as a short term investor. I will not play this long term until I hear about REVENUE, but when that time comes I am going to jump in as fast as lightning and definitely hold long!
Thanks for your input.
GO OWCP
$OWCP
$OWCP
$OWCP
OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Revolutionizing Power Distribution with Sensitron Some days, the tech world dishes out real game-changers, and looks like November 6, 2026, was one of those days. Sensitron Semiconductor dropped a bombshell with their SPHM/SEHM Series—a brand-new lineup of programmable 16-channel Solid State Power Controllers (SSPCs). Tailored for the grueling demands of 270VDC power...
Continue Reading
The cosmos isn't just a playground for astronauts. It's a proving ground for the next wave of medical innovation, courtesy of Esperto Medical. They're trotting into uncharted territory with the Translational Research Institute for Space Health (TRISH) grant in hand, determined to transform healthcare both in space and on our own turf. Groundbreaking Tech for Extreme...
Continue Reading
Urban Solutions: More Than Just Tech Buzzwords In the bustling city of Barcelona, the Smart City Expo World Congress (SCEWC) 2026 wrapped up with a throng of experts and urban innovators declaring the undeniable impact of smart city initiatives. More than just a glitzy showcase, this event was a deep dive into practical solutions for today's urban headaches like...
Continue Reading
Investor Deadline Looms for BETR Losses Ah, the tangled web of finance promises and posturing! Investors in Better Home & Finance Holding Company (NASDAQ: BETR) are now standing at a financial crossroads, thanks to an unfolding legal drama. You've got until November 20, 2026, to align your ducks and join a federal securities class action lawsuit, put forth by Hagens...
Continue Reading
Moving Up the Rankings Ladder Mount St. Mary's University has been making waves not only on campus but in the highly competitive world of college rankings. The institution has managed to climb the ranks in the 2026–27 U.S. News & World Report Best Colleges rankings, a feat that's not just some idle happenstance. The Numbers Speak If you've been paying attention, the...
Continue Reading
HSBC Raises Stake in Its Own Game See folks, when HSBC announces it's bumping up the ceiling on buying back its own securities, you know there's a game afoot in the capital management arena. They raised the offering to snag up these $3 billion 6% perpetuals from $1 billion up to a hefty $1.5 billion. It's like they’re saying, 'Hey, let’s tighten the belt and make sure...
Continue Reading
Shifting Legislative Sands for Business Giddy up, folks! The political tectonic plates just shifted with Democrats grabbing the reins of Congress. For businesses trying to keep their heads above water or score a victory lap, this change could mean adjusting to new winds blowing from Capitol Hill. What could this Democratic majority spell out for taxes, tariffs, and...
Continue Reading
Big Numbers in the Needle Game When you're staring down the numbers popping out of this pen needles market projection, it's hard to ignore—shooting from a respectable $2.16 billion in 2026 to a hefty $3.37 billion by 2031. We're talking a 9.3% CAGR that'll have investors pulling out their calculators or maybe rubbing their hands in downright glee, depending on their...
Continue Reading
LaserAway's New Chapter in Paramus Out of the glitz of Los Angeles and into the hustle of Paramus, LaserAway's latest clinic isn't just a ribbon-cutting ceremony—it's a milestone in the aesthetic dermatology space. Boasting its 241st location, LaserAway is marking twenty years of relentless expansion without ever closing a single clinic. Now that's a track record that'd...
Continue Reading
NovoTech's Moment in the Spotlight Every once in a while, a small fish manages to swim with the sharks and come out shining. NovoTech, a relative newcomer in the swarm of patent law firms, has snagged itself a spot in the inaugural Chambers USA Spotlight 2027 DC Metro Guide. Considering they're playing in the bustling intellectual property scene, this is no small...
Continue Reading
Top 5 Most Recently Viewed Articles
U.S. Bitcoin Reserve Expectations Rise As BTC Hits New Heights Recent insights shared by Anthony Pompliano, a notable venture capitalist and podcast host, indicate that the expectation for a U.S. Bitcoin Reserve has surged significantly. With Bitcoin hiked to around $106,000 for a brief moment, it's clear that excitement is brewing in the crypto space. The current Bitcoin...
Continue Reading
3M Company's Impressive Third-Quarter Earnings 3M Company (NYSE: MMM) has recently announced a strong performance in its third quarter, exceeding analysts' expectations. The company revealed figures indicating a surge in both sales and earnings, contributing to a positive outlook for the remainder of the fiscal year. Financial Highlights from the Q3 Results 3M reported...
Continue Reading
Trump's Potential Move to Sell Media Interests Former President Donald Trump is gearing up to make a major financial decision that could significantly impact the market. As September comes to a close, he is considering selling off his entire stake in Trump Media & Technology Group, the parent company of his social media platform, Truth Social. This move could have serious...
Continue Reading
Overview of Recent Market Trends The U.S. stock market has shown promising signs recently, indicating a positive shift in investor sentiment. As reported by the CNN Money Fear and Greed index, market sentiment has improved, landing in the 'Neutral' zone. U.S. Stocks Experience Notable Gains On a recent trading day, U.S. stocks reported upward movements with the Nasdaq...
Continue Reading
Amplify Expands Digital Asset Offerings Amplify ETFs is making significant strides in the digital asset sector by launching two distinct exchange-traded funds (ETFs) that tap into the infrastructure powering the blockchain’s evolution. This move allows investors to engage with the crypto ecosystem without the necessity of owning actual cryptocurrencies. The Amplify...
Continue Reading